These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 25092710

  • 21. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
    Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A.
    Retrovirology; 2010 Mar 16; 7():21. PubMed ID: 20233398
    [Abstract] [Full Text] [Related]

  • 22. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, Study 934 Team.
    J Acquir Immune Defic Syndr; 2009 Oct 01; 52(2):209-21. PubMed ID: 19644384
    [Abstract] [Full Text] [Related]

  • 23. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH, Ellis GM, Chintu N, Cantrell RA, Sinkala M, Aldrovandi GM, Warrier R, Mbewe F, Nakamura K, Stringer EM, Frenkel LM, Stringer JS.
    AIDS Res Hum Retroviruses; 2009 Nov 01; 25(11):1099-106. PubMed ID: 19886836
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
    Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, GS-US-236-0102 study team.
    Lancet; 2012 Jun 30; 379(9835):2439-2448. PubMed ID: 22748591
    [Abstract] [Full Text] [Related]

  • 28. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.
    Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A.
    Antimicrob Agents Chemother; 2009 Mar 30; 53(3):896-902. PubMed ID: 19075072
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D.
    Lancet Infect Dis; 2014 Jul 30; 14(7):581-9. PubMed ID: 24908551
    [Abstract] [Full Text] [Related]

  • 32. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
    Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W.
    J Virol; 2009 Oct 30; 83(20):10358-65. PubMed ID: 19656878
    [Abstract] [Full Text] [Related]

  • 33. Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
    Andreatta KN, Miller MD, White KL.
    Antimicrob Agents Chemother; 2016 Feb 30; 60(2):757-65. PubMed ID: 26574015
    [Abstract] [Full Text] [Related]

  • 34. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
    Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S, SPARE study team.
    PLoS One; 2013 Feb 30; 8(8):e73639. PubMed ID: 23951362
    [Abstract] [Full Text] [Related]

  • 35. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 Feb 30; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 36. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
    Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K.
    Antivir Chem Chemother; 2009 Feb 30; 19(4):165-76. PubMed ID: 19374144
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.
    Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF.
    Antimicrob Agents Chemother; 2013 Mar 30; 57(3):1262-9. PubMed ID: 23263005
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb 30; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.